Mogensen, Ann-Katrine Birkelund http://orcid.org/0000-0002-2562-7091
Christiansen, Helle http://orcid.org/0000-0003-4893-4622
De Bruin, Marie Louise http://orcid.org/0000-0001-9197-7068
Hallgreen, Christine Erikstrup http://orcid.org/0000-0002-7916-3915
Article History
Accepted: 2 August 2022
First Online: 13 August 2022
Declarations
:
: No external funds were used in the preparation of this article.
: Christine Erikstrup Hallgreen is employed by the University of Copenhagen at the Copenhagen Centre for Regulatory Science (CORS). CORS is a cross-faculty university anchored institution involving various public (Danish Medicines Agency, Copenhagen University) and private stakeholders (Novo Nordisk, Lundbeck, Ferring Pharmaceuticals, LEO Pharma) as well as patient organisations (Rare Diseases Denmark). The centre is purely devoted to the scientific aspects within the regulatory field and with a patient-oriented focus whilst the research is not a company-specific product or directly company related. Helle Christiansen is a PhD student at CORS. Her project is funded by a grant from Lundbeck A/S to the CORS. At the time of the study, Marie Louise De Bruin was an employee at CORS. Currently, she is employed by Utrecht University to conduct research under the umbrella of the Utrecht Centre for Pharmaceutical Policy and Regulation. This centre receives no direct funding or donations from private parties, including the pharma industry. Research funding from public-private partnerships, for example, IMI, The Escher Project (ExternalRef removed), is accepted under the condition that no company-specific study is conducted. The centre has received unrestricted research funding from public sources, for example, World Health Organization, Netherlands Organisation for Health Research and Development, the Dutch National Health Care Institute, European Commission Horizon 2020, the Dutch Medicines Evaluation Board and the Dutch Ministry of Health. Ann-Katrine Birkelund Mogensen was during the study period from August 2020 to January 2021 a master thesis student at the University of Copenhagen at CORS. During this period, AKM worked part-time as a student assistant in the generic pharmaceutical company Sandoz A/S. After graduation in January 2021, and currently, AKM is working at Sandoz A/S. Sandoz A/S was not involved in any aspect of this study.
: Not applicable.
: Not applicable.
: Not applicable.
: Data collected for the purpose of this study are included in this published article as supplementary information.
: Not applicable.